Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0004135 (
ATM
)
13,001
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Lamina-associated polypeptide 1 (LAP1) is a type II transmembrane protein of the inner nuclear membrane encoded by the human gene TOR1AIP1. LAP1 is involved in maintaining the nuclear envelope structure and appears be involved in the positioning of lamins and chromatin. To date, LAP1's precise function has not been fully elucidated but analysis of its interacting proteins will permit unraveling putative associations to specific cellular pathways and cellular processes. By assessing public databases it was possible to identify the LAP1 interactome, and this was curated. In total, 41 interactions were identified. Several functionally relevant proteins, such as TRF2,
TERF2IP
, RIF1,
ATM
, MAD2L1 and MAD2L1BP were identified and these support the putative functions proposed for LAP1. Furthermore, by making use of the Ingenuity Pathways Analysis tool and submitting the LAP1 interactors, the top two canonical pathways were "Telomerase signalling" and "Telomere Extension by Telomerase" and the top functions "Cell Morphology", "Cellular Assembly and Organization" and "DNA Replication, Recombination, and Repair". Once again, putative LAP1 functions are reinforced but novel functions are emerging.
...
PMID:Lamina Associated Polypeptide 1 (LAP1) Interactome and Its Functional Features. 2678 40
The contribution of recently established or candidate susceptibility genes to melanoma missing heritability has yet to be determined. Multigene panel testing could increase diagnostic yield and better define the role of candidate genes. We characterized 273
CDKN2A/ARF
and
CDK4-
negative probands through a custom-designed targeted gene panel that included
CDKN2A/ARF, CDK4, ACD, BAP1, MITF, POT1,
TERF2IP
,
ATM
,
and
PALB2.
Co-segregation, loss of heterozygosity (LOH)/protein expression analysis, and splicing characterization were performed to improve variant classification. We identified 16 (5.9%) pathogenic and likely pathogenic variants in established high/medium penetrance cutaneous melanoma susceptibility genes (
BAP1, POT1, ACD, MITF,
and
TERF2IP
), including two novel variants in
BAP1
and 4 in
POT1
. We also found four deleterious and five likely deleterious variants in
ATM
(3.3%). Thus, including potentially deleterious variants in
ATM
increased the diagnostic yield to about 9%. Inclusion of rare variants of uncertain significance would increase the overall detection yield to 14%. At least 10% of melanoma missing heritability may be explained through panel testing in our population. To our knowledge, this is the highest frequency of putative
ATM
deleterious variants reported in melanoma families, suggesting a possible role in melanoma susceptibility, which needs further investigation.
...
PMID:Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD,
ATM, BAP1,
and
POT1
. 3232 37